SOUTH SAN FRANCISCO, Calif. (AP) _ Allogene Therapeutics Inc. (ALLO) on Wednesday reported a loss of $79.9 million in its first quarter.

The South San Francisco, California-based company said it had a loss of 56 cents per share.

The results exceeded Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for a loss of 59 cents per share.

The immuno-oncology company posted revenue of $61,000 in the period.

Allogene Therapeutics shares have fallen 37% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $9.42, a drop of 68% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALLO at https://www.zacks.com/ap/ALLO

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News